Karyopharm Therapeutics 宣布,将寻求优先审评资格,针对其药物 Selinexor 与 Ruxolitinib 联合使用的方案,提交补充新药申请(sNDA)。
Karyopharm Therapeutics 宣布,将寻求优先审评资格,针对其药物 Selinexor 与 Ruxolitinib 联合使用的方案,提交补充新药申请(sNDA)。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.